Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

darusentan

Known as: (+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid, benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (S)- 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2010
2010
To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Hypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2008
2008
Objective: To summarize the role of the endothelin system (ETS) in cardiovascular disease (CVD) and evaluate the potential… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2007
2007
In this phase 2, randomized, double-blind, placebo-controlled forced dose-titration study, 115 patients with resistant… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Endothelin-receptor blockade provides haemodynamic benefit in experimental and clinical heart failure. We aimed to… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
The cause of focal-segmental glomerulosclerosis as a consequence of physiological aging, which is believed to be inexorable, is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2003
2003
The present study evaluated the effects of long-term treatment with the endothelin A (ET(A)) receptor antagonist darusentan… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND The antihypertensive efficacy and safety of darusentan, a new selective endothelin, antagonist was investigated… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
BACKGROUND The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?